In yesterday’s Wall Street session, Baudax Bio Inc (NASDAQ:BXRX) shares traded at $0.37, down -18.12% from the previous session.
1 analysts cover Baudax Bio Inc (NASDAQ:BXRX), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $24.00 and a low of $24.00, we find $24.00. Given the previous closing price of $0.45, this indicates a potential upside of 5233.33 percent. BXRX stock price is now -26.86% away from the 50-day moving average and -74.38% away from the 200-day moving average. The market capitalization of the company currently stands at $3.40M.
The stock has received a hold rating from 1 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $24.00 as their price target over the next twelve months.
With the price target of $13, JMP Securities recently initiated with Mkt Outperform rating for Baudax Bio Inc (NASDAQ: BXRX).
In other news, HENWOOD GERALDINE, President and CEO bought 1,200 shares of the company’s stock on Dec 15. The stock was bought for $3,057 at an average price of $2.55. Upon completion of the transaction, the President and CEO now directly owns 2,427 shares in the company, valued at $897.99. A total of 2.28% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BXRX stock. A new stake in Baudax Bio Inc shares was purchased by CREATIVE PLANNING during the first quarter worth $17,000. JANE STREET GROUP, LLC invested $10,000 in shares of BXRX during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in Baudax Bio Inc valued at approximately $4,000. In total, there are 15 active investors with 19.57% ownership of the company’s stock.
On Friday morning Baudax Bio Inc (NASDAQ: BXRX) stock kicked off with the opening price of $0.3780. During the past 12 months, Baudax Bio Inc has had a low of $0.30 and a high of $12.24. The fifty day moving average price for BXRX is $0.4965 and a two-hundred day moving average price translates $1.4276 for the stock.
The latest earnings results from Baudax Bio Inc (NASDAQ: BXRX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$1.52, beating analysts’ expectations of -$2.04 by 0.52. This compares to -$17.70 EPS in the same period last year. The net profit margin was -6281.93% and return on equity was -4392.67% for BXRX.
Baudax Bio Inc(BXRX) Company Profile
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
